OverviewSuggest Edit

Akouos is a company that develops targeted gene therapies designed to treat hearing disorders. Its therapies restore and preserve hearing in genetically-defined patient populations from a single genetic mutation to ototoxic drug exposure and to the aging process, enabling patients to hear properly and getting the functional proteins required for hearing.
TypePrivate
Founded2017
HQBoston, MA, US
Websiteakouos.com

Latest Updates

Employees (est.) (Sept 2021)84(+4%)
Job Openings15
Cybersecurity ratingAMore

Key People/Management at Akouos

Manny Simons

Manny Simons

Founder and CEO
Michael McKenna

Michael McKenna

Chief Medical Officer & Co-Founder
John Connelly

John Connelly

Senior Vice President, Portfolio Strategy and R&D Operations
Greg Robinson

Greg Robinson

Chief Scientific Officer
William Sewell

William Sewell

Founder
Sachiyo Minegishi

Sachiyo Minegishi

Chief Financial Officer
Show more

Akouos Office Locations

Akouos has an office in Boston
Boston, MA, US (HQ)
645 Summer St #200
Show all (1)

Akouos Financials and Metrics

Summary Metrics

Founding Date

2017

Akouos total Funding

$162.5 m

Akouos latest funding size

$105 m

Time since last funding

2 years ago

Akouos investors

Akouos's latest funding round in March 2020 was reported to be $105 m. In total, Akouos has raised $162.5 m
Show all financial metrics

Akouos Cybersecurity Score

Cybersecurity ratingPremium dataset

A

95/100

SecurityScorecard logo

Akouos Online and Social Media Presence

Embed Graph

Akouos News and Updates

Akouos to Present at Upcoming September Virtual Investor Conferences

BOSTON, Sept. 07, 2021 (GLOBE NEWSWIRE) -- Akouos, Inc. (“Akouos”) (NASDAQ: AKUS), a precision genetic medicine company dedicated to developing potential gene therapies for individuals living with disabling hearing loss worldwide, today announced that Manny Simons, Ph.D., M.B.A., co-founder, presi…

Akouos Announces European Commission Designation of AK-OTOF for the Treatment of Otoferlin Gene-Mediated Hearing Loss as an Orphan Drug

BOSTON, Aug. 11, 2021 (GLOBE NEWSWIRE) -- Akouos, Inc. (NASDAQ: AKUS), a precision genetic medicine company dedicated to developing potential gene therapies for individuals living with disabling hearing loss worldwide, today announced that the European Medicines Agency (EMA) Committee for Orphan M…

Akouos to Present at Upcoming August Virtual Investor Conferences

BOSTON, Aug. 04, 2021 (GLOBE NEWSWIRE) -- Akouos, Inc. (“Akouos”) (NASDAQ: AKUS), a precision genetic medicine company dedicated to developing potential gene therapies for individuals living with disabling hearing loss worldwide, today announced that Manny Simons, Ph.D., M.B.A., co-founder, presid…

Akouos Presents Nonclinical Data Supporting Future Clinical Development of AK-OTOF and AK-antiVEGF at the American Society of Gene and Cell Therapy 24th Annual Meeting

- Intracochlear delivery of a dual AAVAnc80 vector encoding human otoferlin results in full-length protein expression in inner hair cells of non-human primates and in durable protein expression sufficient for sustained restoration of auditory function in Otof knockout mice

Akouos Appoints Dr. Kathy Reape as Chief Development Officer

BOSTON, May 07, 2021 (GLOBE NEWSWIRE) -- Akouos, Inc. (NASDAQ: AKUS), a precision genetic medicine company dedicated to developing potential gene therapies for individuals living with disabling hearing loss worldwide, today announced the appointment of Dr. Kathy Reape as chief development officer.…

Akouos to Present at Bank of America 2021 Virtual Healthcare Conference

BOSTON, May 07, 2021 (GLOBE NEWSWIRE) -- Akouos, Inc. (“Akouos”) (NASDAQ: AKUS), a precision genetic medicine company dedicated to developing potential gene therapies for individuals living with disabling hearing loss worldwide, today announced that Manny Simons, Ph.D., M.B.A., co-founder, preside…
Show more

Akouos Blogs

Akouos to Present Data from Inner Ear Gene Therapy Platform at 23rd ASGCT Annual Meeting

Boston, Mass. – May 11, 2020 – Akouos, a precision genetic medicine company developing gene therapies to potentially restore, improve and preserve hearing, announced today that data from its inner ear gene therapy platform will be presented during the 23rd American Society of Gene and Cell Therapy (…

Akouos Closes $105 Million Series B Financing

Akouos Closes $105 Million Series B Financing Appoints Vicki Sato, Ph.D., and Heather Preston, M.D., to Board of Directors Boston, Mass. – March 3, 2020 – Akouos, Inc. (“Akouos”), a precision genetic medicine company developing potential gene therapies to restore, improve or preserve hearing, today …

Akouos Announces New Data at the Association for Research in Otolaryngology Midwinter Meeting

Boston, Mass. – January 24, 2020 – Akouos, a precision genetic medicine company developing gene therapies to potentially improve and preserve hearing, announced today that data from its inner ear gene therapy platform will be presented during the 43rd Annual Midwinter Meeting of the Association for …

Akouos Announces Senior Leadership Team Appointments

Boston, Mass. – January 9, 2020 – Akouos, a precision genetic medicine company developing potential gene therapies to restore and preserve hearing, today announced two key senior leadership appointments. Morgan Molloy joins the team as chief corporate development officer, and Karoline Shair, Ph.D., …

Akouos Appoints Rabia Gurses Ozden, M.D., as Chief Development Officer

Akouos Appoints Rabia Gurses Ozden, M.D., as Chief Development Officer BOSTON – October 24, 2019 – Akouos, a precision genetic medicine company developing gene therapies to restore and preserve hearing, today announced the appointment of Rabia Gurses Ozden, M.D., as chief development officer. “We ar…
Show more

Akouos Frequently Asked Questions

  • When was Akouos founded?

    Akouos was founded in 2017.

  • Who are Akouos key executives?

    Akouos's key executives are Manny Simons, Michael McKenna and John Connelly.

  • How many employees does Akouos have?

    Akouos has 84 employees.

  • Who are Akouos competitors?

    Competitors of Akouos include Teknova, Genematrix and OmniSeq.

  • Where is Akouos headquarters?

    Akouos headquarters is located at 645 Summer St #200, Boston.

  • Where are Akouos offices?

    Akouos has an office in Boston.

  • How many offices does Akouos have?

    Akouos has 1 office.